Stanford BMT-CT ASH Abstracts 2023: Oral Abstracts

152 Heterogeneity of Human Invariant Natural Killer T Cells, Including Novel Naïve-like CD8⁺ and Temra-like CD4^-CD8^- Populations, Revealed through Single Cell RNA-Sequencing

Melissa Mavers, MD, PhD^1*, Derek Hollingsworth, MS^2*, Reyka G. Jayasinghe, PhD^3*, Chaiyaporn Boonchalermvichian, MD, PhD⁴, Biki Gupta, PhD^4*, Hao Yan, PhD^4*, Jeanette Baker, PhD^4*, Beruh Dejene^5*, Kenneth I. Weinberg, MD^5* and Robert S. Negrin, MD⁴

https://ash.confex.com/ash/2023/webprogram/Paper182442.html

 

230 Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, MD¹, Jeremy M. Pantin, MD^2*, Rasmus T. Hoeg, MD^3*, Lori S. Muffly, MD⁴, Sagar S. Patel, MD⁵, Arpita Gandhi, MD⁶, Robert Lowsky, MD^7*, Amandeep Salhotra, MD⁸, Bhagirathbhai Dholaria, MBBS⁹, Edmund K. Waller, MD¹⁰, Samer A. Srour, MD¹¹, Anna Pavlova, MD, PhD¹², Nathaniel B. Fernhoff, PhD^13*, Irene Agodoa, MD¹³, J. Scott McClellan, MD, PhD¹³, Mehrdad Abedi, MD^14*, Robert S. Negrin, MD¹⁵ and Everett H. Meyer, MD, PhD¹⁶

https://ash.confex.com/ash/2023/webprogram/Paper186749.html

 

261 Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset

Christa L Meyer, MS^1*, Theresa H.M. Keegan, PhD, MS², Ann Brunson, MS^2*, Jeffery J. Auletta, MD^1,3, Lindsay M. Morton, PhD^4*, Ted Wun, MD², Sara J. Schonfeld, PhD^4*, Bryan Valcarcel, MD, MPH⁴, Renata Abrahao, MD, MSc, PhD^2*, Rafeek Yusuf, MD, PhD^1* and Lori S. Muffly, MD⁵

https://ash.confex.com/ash/2023/webprogram/Paper179457.html

 

360 CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Mark P. Hamilton, MD¹, Brian J. Sworder, MD, PhD^2,3, Stefan K. Alig, MD⁴, Zinaida Good, PhD^5*, Jan Boegeholz, MD⁶, Joseph Schroers-Martin, MD^6*, John Tamaresis, PhD^7*, Mohammad Shahrokh Esfahani, PhD^4*, Ying Lu, PhD^7*, Mari Olsen^4*, Chih Long Liu^4*, Zachary Ehlinger^8*, Moksha Desai^8*, Felicia Liu-Fei^9*, Lori S. Muffly, MD¹⁰, Robert S. Negrin, MD¹¹, Sally Arai, MD¹², Laura Johnston¹³, Robert Lowsky, MD^14*, Everett H. Meyer, MD, PhD¹⁵, Andrew R. Rezvani, MD, BA^16*, Judith Shizuru, MD, PhD^17*, Wen-Kai Weng, MD, PhD¹⁸, Parveen Shiraz, MD^13*, Surbhi Sidana, MD¹³, Sushma Bharadwaj, MD, MS¹⁸, Melody Smith, MD, MS¹⁹, Saurabh Dahiya^18*, Bita Sahaf, PhD, MSc^20*, Maximilian Diehn, MD, PhD^21*, Matthew J. Frank, MD, PhD¹⁸, Crystal L. Mackall, MD²², David M. Kurtz, MD, PhD⁴, David B. Miklos, MD, PhD^18,22 and Ash A. Alizadeh, MD, PhD^4,2

https://ash.confex.com/ash/2023/webprogram/Paper182522.html

 

470 Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

Arpita Gandhi, MD¹, Andrew Artz, MD, MS², Catherine J. Lee, MD³, Ankur Varma, MD⁴, Bart L. Scott, MD⁵, Hye-Sook Kwon, PhD^6*, Minyoung Youn, PhD^7*, Chikako Yanagiba^6*, Jeyakavitha Arulprakasam^7*, Anne Le^7*, Judith Shizuru, MD, PhD^8*, Wendy W Pang, MD, PhD⁶ and Lori S. Muffly, MD⁹

https://ash.confex.com/ash/2023/webprogram/Paper185533.html

 

1027 Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Surbhi Sidana, MD¹, Nausheen Ahmed, MD², Othman S Akhtar, MD³, Michael Heim, MS^4*, Ruta Brazauskas, PhD^5,6*, Doris K. Hansen, MD^7*, Christopher Ferreri, MD^8*, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP⁹, Aimaz Afrough, MD^10*, Larry D. Anderson Jr., MD, PhD¹¹, Binod Dhakal, MD, MS^12*, Devender Dhanda, PhD^13*, Lohith Gowda, MD^14*, Hamza Hashmi, MD^15*, Melanie Harrison^16*, Amani Kitali, MBA, MPH, PMP^13*, Sayeef Mirza, MD, MPH¹⁷, Jinalben Patel, MPH^6*, Pallavi Patwardhan^16*, Saad Z Usmani, MD¹⁸, Krina K. Patel, MD, MSc¹⁹, Siddhartha Ganguly, MD²⁰ and Marcelo Pasquini, MD, MS⁶

https://ash.confex.com/ash/2023/webprogram/Paper181762.html

 

1030 Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Gregory W Roloff, MD¹, Ibrahim Aldoss², Noam E. Kopmar, MD³, Chenyu Lin, MD⁴, Simone E. Dekker, MD, PhD⁵, Vishal K Gupta, MD⁶, Nikeshan Jeyakumar, MD^7*, Timothy E O'Connor, MD⁸, Amy Zhang, PhD^9*, Katharine Miller, PhD, MPH^9*, Kaitlyn C Dykes, MD^10*, Mohamed Ahmed¹¹, Hector Zambrano^12*, Danielle Bradshaw, MD^13*, Santiago Mercadal, MD^14*, Marc Schwartz, MD^15*, Sean Tracy, MD, PhD¹⁶, Bhagirathbhai Dholaria, MBBS¹⁷, Michal Kubiak, MD¹⁸, Akash Mukherjee, MD^19*, Navneet Majhail, MD²⁰, Minoo Battiwalla, MD²⁰, Luke Mountjoy, DO²¹, Shahbaz A. Malik, MD²², John Mathews, MD^23*, Paul Shaughnessy, MD²⁴, Aaron C. Logan, MD, PhD²⁵, Abdullah Ladha, MD^26*, George Yaghmour, MD²⁶, Anjali S. Advani, MD²⁷, Maryann Stefan^27*, Caitlin Guzowski, MBA^28*, Rasmus T. Hoeg, MD^29*, Talal Hilal, MD³⁰, Jozal Moore, MD³¹, Kristen M. O'Dwyer, MD³¹, Stephanie B. Tsai, MD, MS⁸, Joshua Sasine, MD¹¹, Melhem M. Solh, MD²⁸, Catherine J. Lee, MD³², Vamsi K. Kota, MD¹⁸, Divya Koura, MD¹⁰, Muthu Veeraputhiran, MD^19*, Betsy Blunk^12*, Jessica T. Leonard, MD³³, Veronika Bachanova, MD, PhD³⁴, Wendy Stock, MD¹, Ahmed Galal, MD⁴, Vinod Pullarkat, MD², Ryan D Cassaday, MD³, Bijal D. Shah, MD³⁵, Rawan Faramand, MD³⁵ and Lori S. Muffly, MD⁹

https://ash.confex.com/ash/2023/webprogram/Paper182531.html

 

1032 Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, MD, FRCPC¹, Michael D. Jain, MD, PhD², Loretta J. Nastoupil, MD³, John Tamaresis, PhD^4*, Armin Ghobadi, MD⁵, Yi Lin, MD, PhD⁶, Lazaros J. Lekakis^7*, Patrick M. Reagan, MD⁸, Olalekan O. Oluwole, MBBS⁹, Joseph P McGuirk, DO¹⁰, Abhinav Deol, MD^11*, Kathleen Dorritie, MD¹², Alison R Sehgal, MD¹², Andre Goy, MD¹³, Brian T. Hill, MD¹⁴, Charalambos Andreadis, MD¹⁵, Javier L. Munoz¹⁶, Matthew L. Ulrickson, MD¹⁷, Jason Westin, MD¹⁸, Julio C. Chavez, MD¹⁹, Dilan A Patel^20*, Miriam T. Jacobs, MD^21*, Radhika Bansal, MBBS^6*, N. Nora Bennani, MD²², Vivek Patel, MD⁹, Aaron P. Rapoport, MD²³, Julie M. Vose, MD, MBA²⁴, David B. Miklos, MD, PhD²⁵, Sattva S. Neelapu, MD²⁶, Frederick L. Locke, MD², Matthew A. Lunning, DO, FACP^27* and Saurabh Dahiya^25*

https://ash.confex.com/ash/2023/webprogram/Paper179868.html

 

1037 Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible

Yi-Jiun Su, MD^1,2*, Anne Marijn Kramer, MD, PhD^3,4*, Mark P. Hamilton, MD^2,4, Neha Agarwal, MS^2,4*, Steven Feldman, PhD^4*, Bita Sahaf, PhD, MSc^4,5*, Adam Kuo, MS^4,5*, Crystal L. Mackall, MD^2,4,6, Lori S. Muffly, MD^2,4, David B. Miklos, MD, PhD^4,7 and Matthew J. Frank, MD, PhD^4,7

https://ash.confex.com/ash/2023/webprogram/Paper185413.html

 

1 Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Daniel Wolff^1*, Corey Cutler^2,3, Stephanie J. Lee^4*, Iskra Pusic⁵, Henrique Bittencourt⁶, Jennifer White, MD, MSc, FRCPC^7*, Mehdi Hamadani, MD⁸, Sally Arai, MD⁹, Amandeep Salhotra, MD¹⁰, Jose A. Pérez-Simón¹¹, Amin Alousi^12*, Hannah Choe, MD¹³, Mi Kwon¹⁴, Arancha Bermúdez^15*, Inho Kim^16*, Gerard Socié¹⁷, Vedran Radojcic¹⁸, Timothy O'Toole^19*, Chuan Tian^20*, Peter Ordentlich^19*, Zachariah DeFilipp²¹ and Carrie L. Kitko, MD²²

https://ash.confex.com/ash/2023/webprogram/Paper186963.html

 

103 Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Michael Roderick Cook, MD¹, Roni Shouval, MD, PhD², Miguel-Angel Perales, MD³, Evandro Bezerra, MD⁴, Alex Niu, MD^5*, Saurabh Dahiya^6*, Loretta J. Nastoupil, MD⁷, Caron A Jacobson, MD, MMSc⁸, Elizabeth Lihua Budde, MD, PhD⁹, Amanda L. Olson, MD¹⁰, Brent R. Logan, PhD^11*, Zhen-Huan Hu, MPH^12*, Hai-Lin Wang, MPH^12*, Zhong-Cheng Luo, PhD^12*, Jenny J. Kim, MD, MS¹³, Harry W. Smith, BSc MSc^12*, Andrew Lee, MD^12*, Fang Sun, MD, PhD^12*, Marcelo Pasquini, MD, MS¹⁴ and Frederick L. Locke, MD¹⁵

https://ash.confex.com/ash/2023/webprogram/Paper175034.html

 

106 Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, MD¹, Caron A Jacobson, MD, MMSc², Ian W. Flinn, MD, PhD³, Brian T. Hill, MD⁴, Wen-Kai Weng, MD, PhD⁵, Luke Mountjoy, DO⁶, Oluwole Olalekan, MD, MBBS, MPH^7*, Dan Zheng, PhD^8*, Ana Nunes, PharmD^8*, Wangshu Zhang, PhD^8*, Rhine R. Shen, PhD^8*, Ioana Kloos, MD^8* and Michael L. Wang, MD⁹

https://ash.confex.com/ash/2023/webprogram/Paper174273.html

 

107 Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Swetha Kambhampati, MD¹, Nausheen Ahmed, MD², Mehdi Hamadani, MD³, Soyoung Kim, PhD^3*, Michael T. Hemmer, MS^4*, Natalie S. Grover, MD⁵, Mazyar Shadman, MD, MPH⁶, Amer Beitinjaneh, MD, MPH, MSc^7*, Elizabeth Lihua Budde, MD, PhD⁸, James Gerson, MD⁹, Caron A Jacobson, MD, MMSc¹⁰, Frederick L. Locke, MD¹¹, Dwivedy S. Nasta, MD^12*, Michael L. Wang, MD¹³, Wen-Kai Weng, MD, PhD¹⁴, Jiali Yan, MS^4*, Ana Nunes, PharmD^4*, David Dalton, PharmD^4*, James J. Wu, MPH, MSc^4*, Amina Abdeldaim, MD, MPH^4*, Zhen-Huan Hu, MPH^4*, Marcelo Pasquini, MD, MS³ and Alex F. Herrera, MD¹⁵

https://ash.confex.com/ash/2023/webprogram/Paper179269.html

 

 109 The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Andrew Artz, MD, MS¹, Brent R. Logan, PhD^2*, Wael Saber, MD, MS³, Nancy Geller, PhD^4*, Anna Bellach, Ph.D.^4*, Jianqun Kou, MS^5*, William Wood, MD, MPH⁶, John M. McCarty, MD⁷, Thomas G. Knight, MD⁸, Lyndsey Runaas^9*, Laura Johnston¹⁰, Jeremy Walston^11*, Ryotaro Nakamura, MD¹², Tammy Schuler^13*, Asmita Mishra, MD, MBA¹⁴, Joseph Uberti, MD, PhD¹⁵, Parastoo B. Dahi, MD^16*, Jennifer N. Saultz, DO¹⁷, Shannon R McCurdy, MD¹⁸, Lawrence Morris, MD¹⁹, Philip Imus, MD²⁰, William J. Hogan, MD²¹, Kalyan Nadiminti, MBBS²², Vijaya Raj Bhatt, MD²³, Deborah Mattila, BA^24*, Bailey Protz^25*, Steven M. Devine, MD²⁶, Mary M. Horowitz, MD²⁷ and Mohamed Sorror, MD MSc²⁸

https://ash.confex.com/ash/2023/webprogram/Paper173855.html

 

226 Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Mike Mattie, PhD^1*, Melanie Grosso^2*, Aurelie Auguste, PhD^2*, Denis Arnaud, MBA^2*, Frederick L. Locke, MD³, Sattva S. Neelapu, MD⁴, David B. Miklos, MD, PhD⁵, Caron A Jacobson, MD, MMSc⁶, Lazaros J. Lekakis^7*, Yi Lin, MD, PhD⁸, Armin Ghobadi, MD⁹, Jenny J. Kim, MD, MS¹, Jenny Nater^1*, Rhine R. Shen, PhD^10* and Jerome Galon^2,11*

https://ash.confex.com/ash/2023/webprogram/Paper187574.html

 

229 Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCRαβ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia

Rajni Agarwal, MD^1*, Alice Bertaina, MD, PhD², Charmaine Fay Soco, PhD^3*, Gopin Saini^4*, Nivedita Kunte^5*, Lyndsie Hiroshima, PharmD, BCPS, BCPPS^6*, Yan Yi Chan^5*, Hana Willner^7*, Mark L. Krampf, MS^7*, Rofida Nofal, MD^5*, Giulia Barbarito, MS^8*, Sushmita Sen^7*, Matthias Felber, MD^7*, Maite Van Hentenryck^7*, Emily Walck⁷, Amelia Scheck^4*, Supawat Thongthip^4*, Aaron C. Logan, MD, PhD⁹, Kirstin Dougall, MBA^7*, Ali Bouge^7*, Jaap Jan Boelens, MD¹⁰, Janel R. Long-Boyle, PhD, PharmD^11*, Irving L. Weissman, MD¹², Judith Shizuru, MD, PhD^13*, Wendy W Pang, MD, PhD⁵, Kenneth I. Weinberg, MD^14*, Robertson Parkman, MD⁷, Maria-Grazia Roncarolo, MD¹⁵, Matthew Porteus, MD, PhD¹⁶ and Agnieszka Czechowicz, MD, PhD^17,18,19

https://ash.confex.com/ash/2023/webprogram/Paper178400.html

 

235 Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

Mary Eapen, MBBS, MS¹, Joseph Antin, MD^2*, Jakub Tolar, MD, PhD³, Sally Arai, MD⁴, Mitchell Horwitz, MD⁵, Jainqun Kou, MPH^6*, Eric Leifere, PhD^7*, John M. McCarty, MD⁸, Ryotaro Nakamura, MD⁹, Michael A. Pulsipher, MD^10*, Mary M. Horowitz, MD⁶ and H Joachim Deeg, MD^11*

https://ash.confex.com/ash/2023/webprogram/Paper178093.html

 

475 Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Leslie Kean¹, Steven J Siegel^2*, Joseph T Schmalz^3*, Stephanie A Bien^3*, Danielle Scheffey^3*, Catherine Sanders^4*, Harlan Robins^3*, Kristy Applegate^5*, Merav Bar^6*, Saurabh Chhabra^7*, Sung W. Choi, MD, MS⁸, William Clark, MD, MS^9*, Suman r Das^10*, Robert R. Jenq, MD¹¹, Richard J. Jones, MD¹², John Levine, MD¹³, Brent R. Logan, PhD^14*, Hemant S. Murthy, MD¹⁵, Armin Rashidi^16*, Marcie L. Riches, MD¹⁷, Wael Saber, MD, MS¹⁸, Karamjeet S. Sandhu, MD¹⁹, Anthony D. Sung, MD²⁰, Karilyn Larkin^21*, Monzr M. Al Malki, MD²², Mahasweta Gooptu, MD²³, Hany Elmariah, MD, MS²⁴, Amin Alousi^25*, Lyndsey Runaas^26*, Brian C. Shaffer, MD²⁷, Andrew R. Rezvani, MD, BA^28*, Najla El Jurdi, MD^29*, Alison Loren, MD, MSCE³⁰, Mary M. Horowitz, MD³¹, Javier Bolanos-Meade, MD, KHS^32*, Shernan G. Holtan, MD³³, Ami S. Bhatt³⁴, Miguel-Angel Perales, MD³⁵ and Susan DeWolf, MD³⁶

https://ash.confex.com/ash/2023/webprogram/Paper188032.html

 

522 Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Noam E. Kopmar, MD^1,2, Ted Gooley, PhD^3*, Gregory W Roloff, MD⁴, Ibrahim Aldoss⁵, Chenyu Lin, MD⁶, Simone E. Dekker, MD, PhD⁷, Vishal K Gupta, MD⁸, Nikeshan Jeyakumar, MD^9*, Timothy O'connor, MD^10*, Kaitlyn C Dykes, MD^11*, Mohamed Ahmed¹², Hector Zambrano^13*, Danielle Bradshaw, MD^14*, Santiago Mercadal, MD^15*, Marc Schwartz, MD^16*, Sean Tracy, MD, PhD¹⁷, Bhagirathbhai Dholaria, MBBS¹⁸, Michal Kubiak, MD¹⁴, Akash Mukherjee, MD^19*, Navneet Majhail, MD²⁰, Minoo Battiwalla, MD²⁰, Luke Mountjoy, DO²¹, Shabaz Malik, MD^22*, Paul Shaughnessy, MD²³, John Mathews, MD^24*, Aaron C. Logan, MD, PhD²⁵, Abdullah Ladha, MD^26*, George Yaghmour, MD²⁷, Anjali S. Advani, MD²⁸, Maryann Stefan^29*, Caitlin Guzowski, MBA^30*, Rasmus T. Hoeg, MD^31*, Talal Hilal, MD³², Jozal Moore, MD³³, Kristen M. O'Dwyer, MD³³, Stephanie B. Tsai, MD, MS¹⁰, Joshua Sasine, MD³⁴, Melhem M. Solh, MD³⁰, Catherine J. Lee, MD¹⁵, Vamsi K. Kota, MD³⁵, Divya Koura, MD¹¹, Muthu Veeraputhiran, MD^19*, Betsy Blunk^13*, Jessica T. Leonard, MD³⁶, Caspian H. Oliai, MD³⁷, Veronika Bachanova, MD, PhD³⁸, Wendy Stock, MD³⁹, Ahmed Galal, MD⁶, Vinod Pullarkat, MD⁵, Bijal D. Shah, MD⁴⁰, Rawan Faramand, MD⁴¹, Lori S. Muffly, MD⁹ and Ryan D Cassaday, MD^1,2

https://ash.confex.com/ash/2023/webprogram/Paper185107.html

 

602 TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, phd¹, Saurabh Dahiya^2*, M. Lia Palomba, MD³, Alejandro Martin Garcia-Sancho, MD^4*, Juan Luis Reguera, MD^5,6*, John Kuruvilla, MD, FRCPC⁷, Ulrich Jaeger, MD^8*, Guillaume Cartron, MD, Ph-D^9*, Koji Izutsu, MD, PhD¹⁰, Martin Dreyling, MD¹¹, Brad S. Kahl, MD¹², Herve Ghesquieres, MD^13*, Kirit Ardeshna, MD, MA, FRCP^14*, Hideki Goto, MD, PhD^15*, Anna Maria Barbui, MD^16*, Jeremy S. Abramson, MD¹⁷, Peter Borchmann, MD¹⁸, Isabelle Fleury, MD¹⁹, Stephan Mielke, MD²⁰, Alan Skarbnik, MD^21,22, Sven de Vos, MD, PhD^23*, Manali Kamdar, MD^24*, Reem Karmali, MD, MSc²⁵, Andreas Viardot, MD PhD²⁶, Thalia Farazi²⁷, Omotayo Fasan²⁸, James Lymp, PhD^29*, Min Vedal, PhD^29*, Rina Nishii, PhD^28*, Ariel Avilion, PhD^29*, Jessica Papuga, PhD^30* and Loretta J. Nastoupil, MD³¹

https://ash.confex.com/ash/2023/webprogram/Paper179474.html

 

649 Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Corey Cutler¹, Haesook T. Kim, PhD², Hassan El Banna^1*, Elizabeth Halloran, BSN, RN^1*, Emily Matozel^1*, Vincent Ho, MD^1*, John Koreth, MD, MBBS, PhD, DPhil¹, Mahasweta Gooptu, MD¹, Roman M. Shapiro, MD¹, Amar H Kelkar, MD¹, Christopher James Gibson, MD¹, Carol Reynolds, PhD^1*, Michela Ansuinelli, MD^1*, Rayuko Tamada^1*, Chloe Au^1*, Zachariah Defilipp, MD³, Areej El-Jawahri, MD³, Yi-Bin Chen, MD, MS³, Najla El Jurdi, MD⁴, Daniel Weisdorf, MD⁵, Daniel R. Couriel, MD, MS, MBA⁶, Catherine J. Lee, MD⁷, Bita Sahaf, PhD, MSc^8*, Juliana Craig^9*, Kathleen Ji^9*, Robert J. Soiffer, MD¹, David B. Miklos, MD, PhD¹⁰, Joseph Antin, MD^1* and Jerome Ritz, MD¹¹

https://ash.confex.com/ash/2023/webprogram/Paper180142.html

 

668 Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, MD, Ph-D^1*, Alejandro Martin Garcia-Sancho, MD^2*, Juan Luis Reguera, MD^3*, Saurabh Dahiya^4*, Shien Guo, PhD^5*, Ling Shi, PhD^5*, Laurie Eliason, MPH^6*, Jinender Kumar^6*, Thalia Farazi⁷, Omotayo Fasan⁶ and Koji Izutsu, MD, PhD⁸

https://ash.confex.com/ash/2023/webprogram/Paper180175.html

 

671 The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, MD¹, Chenyu Lin, MD², Gregory W Roloff, MD³, Amy Zhang, PhD^4*, Ibrahim Aldoss⁵, Rawan Faramand, MD⁶, Noam E. Kopmar, MD⁷, Kaitlyn C Dykes, MD^8*, Nikeshan Jeyakumar, MD^9*, Simone E. Dekker, MD, PhD¹⁰, Vishal K Gupta, MD¹¹, Mohamed Ahmed¹², Aaron C. Logan, MD, PhD¹³, Hector Zambrano^14*, Danielle Bradshaw, MD^15*, Santiago Mercadal, MD^16*, Marc Schwartz, MD^17*, Sean Tracy, MD, PhD¹⁸, Michal Kubiak, MD¹⁹, Akash Mukherjee, MD^20*, Navneet Majhail, MD²¹, Minoo Battiwalla, MD²¹, Luke Mountjoy, DO²², Shabaz Malik, MD^23*, John Mathews, MD^24*, Paul Shaughnessy, MD²⁵, Abdullah Ladha, MD^26*, George Yaghmour, MD²⁷, Anjali S. Advani, MD²⁸, Maryann Stefan^28*, Caitlin Guzowski, MBA^29*, Rasmus T. Hoeg, MD^30*, Talal Hilal, MD³¹, Jozal Moore, MD³², Joshua Sasine, MD¹², Melhem M. Solh, MD²⁹, Catherine J. Lee, MD³³, Vamsi K. Kota, MD³⁴, Divya Koura, MD⁸, Muthu Veeraputhiran, MD^20*, Betsy Blunk^14*, Jessica T. Leonard, MD³⁵, Caspian H. Oliai, MD³⁶, Veronika Bachanova, MD, PhD³⁷, Wendy Stock, MD³⁸, Ryan D Cassaday, MD⁷, Bijal D. Shah, MD³⁹, Katharine Miller, PhD, MPH^4*, Lori S. Muffly, MD⁴, Ahmed Galal, MD², Stephanie B. Tsai, MD, MS⁴⁰ and Bhagirathbhai Dholaria, MBBS⁴¹

https://ash.confex.com/ash/2023/webprogram/Paper182566.html

 

773 Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Samer A. Srour, MD¹, Amandeep Salhotra, MD², Robert Lowsky, MD^3*, Rasmus T. Hoeg, MD^4*, Edmund K. Waller, MD⁵, Anna Pavlova, MD, PhD⁶, J. Scott McClellan, MD, PhD⁷, Nathaniel B. Fernhoff, PhD^7*, Everett H. Meyer, MD, PhD⁸ and Mehrdad Abedi, MD^9*

https://ash.confex.com/ash/2023/webprogram/Paper189534.html

 

897 Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Shernan G. Holtan, MD¹, Michael J Martens, PhD^2*, Monzr M. Al Malki, MD³, Yvonne Adeduni Efebera, MD, MPH⁴, Carrie L. Kitko, MD⁵, Ran Reshef, MD, MSc⁶, Andrew R. Rezvani, MD, BA^7*, Brian C. Shaffer, MD⁸, Melhem M. Solh, MD⁹, Janny M. Yao, PharmD^10*, Lyndsey Runaas, MD^11*, Hany Elmariah, MD, MS¹², Karilyn T. Larkin, MD¹³, Najla El Jurdi, MD¹⁴, Mahasweta Gooptu, MD¹⁵, Alison W Loren, MD¹⁶, Aric C. Hall, MD^17*, Amin Alousi^18*, Omer Jamy, MD¹⁹, William Clark, MD, MS^20*, Leslie Kean²¹, Ami S. Bhatt²², Miguel-Angel Perales, MD²³, Kristy Applegate^24*, Juan WU^25*, Eric Liefer^26*, Nancy DiFronzo, PhD^27*, Richard J. Jones, MD²⁸, Mary M. Horowitz, MD²⁹, Deborah Mattila, BA^30*, Mehdi Hamadani, MD³¹ and Javier Bolanos-Meade, MD, KHS^32*

https://ash.confex.com/ash/2023/webprogram/Paper187859.html

 

973 Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Mark J. Levis, MD, PhD¹, Mehdi Hamadani, MD², Brent R. Logan, PhD^3*, Richard J. Jones, MD⁴, Anurag K. Singh, MD⁵, Mark R. Litzow, MD⁶, John R. Wingard, MD⁷, Esperanza B. Papadopoulos, MD⁸, Alexander Perl⁹, Robert J. Soiffer, MD¹⁰, Celalettin Ustun, MD¹¹, Masumi Ueda Oshima, MD¹², Geoffrey L Uy, MD¹³, Edmund K. Waller, MD¹⁴, Sumithira Vasu, MD, MBBS¹⁵, Melhem M. Solh, MD¹⁶, Asmita Mishra, MD, MBA¹⁷, Lori S. Muffly, MD¹⁸, Hee-Je Kim^19*, Matthias Stelljes, MD²⁰, Yuho Najima, MD, PhD²¹, Masahiro Onozawa, M.D., Ph.D.²², Kirsty Thomson, MB ChB^23*, Arnon Nagler, MD, M.Sc^24*, Andrew H. Wei, MBBS, PhD²⁵, Guido Marcucci, MD²⁶, Nahla Hasabou, MD^27*, Mathew Rosales, PhD^27*, Jason Hill, PhD^27*, Stanley C. Gill, PhD^27*, Rishita Nuthethi, PhD^27*, Denise King, MS, CCRA^28*, Heather Wittsack, MPH^28*, Adam Mendizabel, PhD^28*, Steven M. Devine, MD²⁹, Mary M. Horowitz, MD³⁰ and Yi-Bin Chen, MD, MS³¹

https://ash.confex.com/ash/2023/webprogram/Paper177929.html

 

Stanford BMT-CT ASH Abstracts 2023: Poster Abstracts

1673 Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection

Snegha Ananth, MBBS¹, Yi-Jiun Su, MD^2*, Mark P. Hamilton, MD³, Neha Agarwal, MS^4*, Wen-Kai Weng, MD, PhD¹, Saurabh Dahiya^1*, Sushma Bharadwaj, MD, MS^1,5, Jayasindhu Mallampet^1*, Melody Smith, MD, MS⁶, Katherine Ann Kong^7*, Abigail Twoy^7*, David B. Miklos, MD, PhD¹ and Matthew J. Frank, MD, PhD¹

https://ash.confex.com/ash/2023/webprogram/Paper188338.html

 

2091 Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL

Anne Marijn Kramer, MD, PhD^1,2,3*, Mark P. Hamilton, MD⁴, Snehit Prabhu, PhD^2*, Moksha Desai^2*, Adam Kuo, MS^5*, Zachary Ehlinger^2*, Neha Agarwal, MS^4*, Yi-Jiun Su, MD^6*, Nikolaos Gkitsas, MSc, BSc^2*, Carley Fowler, MS^2*, Vimal Keerthi^2*, Aidan Retherford^2*, Dorota Klysz, PhD^2*, Ramya Tunuguntla, PhD^2*, Steven Feldman, PhD^2*, Bita Sahaf, PhD, MSc^7*, John H. Baird, MD⁸, Lori S. Muffly, MD⁹, Crystal L. Mackall, MD⁵, David B. Miklos, MD, PhD^5,10, Zinaida Good, PhD^2,6* and Matthew J. Frank, MD, PhD^5,10

https://ash.confex.com/ash/2023/webprogram/Paper187615.html

 

2125 Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, MD, MS¹, Eric Lau, DO², Ayesha Hashmi, MBBS^3*, Mark P. Hamilton, MD⁴, Alexandria Jensen, PhD^5*, Anmol Goyal, MD^1*, Mallika Marar, MD, MBA^3*, Caroline Lee, MD^4*, Snegha Ananth, MBBS¹, Bita Sahaf, PhD, MSc^6*, Jayasindhu Mallampet^1*, Zachary Ehlinger^7*, Shriya Syal, MS^6*, Sunita Patil^6*, Henry Guo, MD, PhD^8*, Melody Smith, MD, MS⁹, Wen-Kai Weng, MD, PhD¹, Matthew J. Frank, MD, PhD¹, Michael S. Binkley, MD, MS^10*, David B. Miklos, MD, PhD¹ and Saurabh Dahiya^1*

https://ash.confex.com/ash/2023/webprogram/Paper187617.html

 

2230 High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, MD¹, Rasmus T. Hoeg, MD^2*, Sagar S. Patel, MD³, Edmund K. Waller, MD⁴, Jeremy M. Pantin, MD^5*, Caspian H. Oliai, MD⁶, J. Scott McClellan, MD, PhD⁷, Anna Pavlova, MD, PhD⁸, Irene Agodoa, MD⁷, Nathaniel B. Fernhoff, PhD^7* and Everett H. Meyer, MD, PhD⁹

https://ash.confex.com/ash/2023/webprogram/Paper188994.html

 

2338 Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD¹, Ashley Bonner^2*, Pearl Wang^2*, Lamees Almuallem^2*, Jigar Desai^3*, Omotayo Fasan³, Thalia Farazi⁴, Jinender Kumar^3* and Saurabh Dahiya^5,6*

https://ash.confex.com/ash/2023/webprogram/Paper178786.html

 

3783 Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)

Anmol Goyal, MD^1*, Sushma Bharadwaj, MD, MS¹, Dasom Lee, MD^2*, Eric Lau, DO³, Mark P. Hamilton, MD⁴, Alexandria Jensen, PhD^5*, Bita Sahaf, PhD, MSc^6*, Shriya Syal, MS^6*, Sunita Patil^6*, Juancarlos E Cancilla^6*, Theresa Latchford^7*, Wen-Kai Weng, MD, PhD¹, Melody Smith, MD, MS⁸, Matthew J. Frank, MD, PhD¹, David B. Miklos, MD, PhD¹ and Saurabh Dahiya^1*

https://ash.confex.com/ash/2023/webprogram/Paper186828.html

 

4240 Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Brandon DaSilva, MD¹, Rutu D. Vyas, CRA^2*, Alicia Darwin, MD^1*, Kathryn Russel, ARNP^3*, Jason Gilbert, MD^4*, Virginia Tan, MD^5*, Himani Darji, MBBS, MPH^6*, Katharine Miller, PhD, MPH^6*, Emily C Liang, MD^2,7, Suravi Raychaudhuri, MD^2,8, Adam S. Duvall, MD, MPH⁹, Michaela Liedtke, MD¹⁰, Wendy Stock, MD¹¹, Ryan D Cassaday, MD², Marc Schwartz, MD^12*, Jessica T. Leonard, MD¹³, Marlise R. Luskin, MD¹⁴ and Lori S. Muffly, MD¹⁵

https://ash.confex.com/ash/2023/webprogram/Paper185176.html

 

4839 CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature

Hrishikesh Srinagesh, MD, MSCR^1*, John H. Baird, MD², Neha Agarwal, MS^1*, Yi-Jiun Su, MD^1*, Anne Marijn Kramer, MD, PhD^3*, Agnes Reschke, MD^1*, Nikeshan Jeyakumar, MD^1*, Sushma Bharadwaj, MD, MS¹, Liora Michal Schultz, MD⁴, Sneha Ramakrishna^5*, Kara L. Davis, DO⁶, Bita Sahaf, PhD, MSc^7*, Steven Feldman, PhD^3*, Crystal L. Mackall, MD⁸, David B. Miklos, MD, PhD⁹, Lori S. Muffly, MD¹ and Matthew J. Frank, MD, PhD⁹

https://ash.confex.com/ash/2023/webprogram/Paper178283.html

 

4876 Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Saurabh Dahiya^1*, Jay Y. Spiegel, MD, FRCPC², Dasom Lee, MD^3*, Turab Mohammed, MD^4*, Forat Lutfi, MD⁵, Anmol Goyal, MD^6*, Caroline Hana^7*, Julio C Chavez, MD⁸, Filip Ionescu, MD⁹, Matthew J. Frank, MD, PhD¹, Sushma Bharadwaj, MD, MS¹⁰, Jose Sandoval-Sus, MD¹¹, Amer M. Beitinjaneh, MD, MS^12*, Lazaros J. Lekakis^13*, Joseph P McGuirk, DO⁵, Frederick L. Locke, MD¹⁴, David B. Miklos, MD, PhD¹ and Michael D. Jain, MD, PhD¹⁴

https://ash.confex.com/ash/2023/webprogram/Paper188918.html

 

4877 The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ibrahim Aldoss¹, Gregory W Roloff, MD², Anjali S. Advani, MD³, Noam E. Kopmar, MD⁴, Chenyu Lin, MD⁵, Simone E. Dekker, MD, PhD⁶, Vishal K Gupta, MD⁷, Nikeshan Jeyakumar, MD^8*, Timothy E O'Connor, MD⁹, Amy Zhang, PhD^10*, Katharine Miller, PhD, MPH^10*, Kaitlyn C Dykes, MD^11*, Mohamed Ahmed¹², Hector Zambrano^13*, Danielle Bradshaw, MD^14*, Santiago Mercadal, MD^15*, Marc Schwartz, MD^16*, Sean Tracy, MD, PhD¹⁷, Bhagirathbhai Dholaria, MBBS¹⁸, Michal Kubiak, MD¹⁴, Akash Mukherjee, MD^19*, Navneet Majhail, MD²⁰, Minoo Battiwalla, MD²⁰, Luke Mountjoy, DO²¹, Shahbaz A. Malik, MD²², John Mathews, MD^23*, Paul Shaughnessy, MD²⁴, Aaron C. Logan, MD, PhD²⁵, Abdullah Ladha, MD^26*, George Yaghmour, MD²⁷, Maryann Stefan^3*, Caitlin Guzowski, MBA^28*, Rasmus T. Hoeg, MD^29*, Talal Hilal, MD³⁰, Jozal Moore, MD³¹, Kristen M. O'Dwyer, MD³¹, Stephanie B. Tsai, MD, MS⁹, Joshua Sasine, MD¹², Melhem M. Solh, MD²⁸, Catherine J. Lee, MD³², Vamsi K. Kota, MD³³, Divya Koura, MD¹¹, Muthu Veeraputhiran, MD^19*, Betsy Blunk^13*, Jessica T. Leonard, MD³⁴, Caspian H. Oliai, MD⁷, Veronika Bachanova, MD, PhD¹⁷, Wendy Stock, MD², Ahmed Galal, MD⁵, Vinod Pullarkat, MD³⁵, Ryan D Cassaday, MD⁴, Bijal D. Shah, MD³⁶, Rawan Faramand, MD³⁷ and Lori S. Muffly, MD⁸

https://ash.confex.com/ash/2023/webprogram/Paper182404.html

 

4878 Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, MD, MS¹, Eric Lau, DO², Anmol Goyal, MD^3*, Mark P. Hamilton, MD⁴, Hrishikesh Srinagesh^5*, Alexandria Jensen, PhD^6*, Shriya Syal, MS^7*, Jayasindhu Mallampet^8*, Theresa Latchford^9*, Bita Sahaf, PhD, MSc^7*, Wen-Kai Weng, MD, PhD⁸, Melody Smith, MD, MS¹⁰, Holden T Maecker, PhD^11*, Matthew J. Frank, MD, PhD⁸, David B. Miklos, MD, PhD⁸ and Saurabh Dahiya^8*

https://ash.confex.com/ash/2023/webprogram/Paper188166.html

 

1761 Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten, MD, PhD¹, Umar Farooq², Aaron P. Rapoport, MD³, Frederick L. Locke, MD⁴, Lori A. Leslie, MD⁵, Armin Ghobadi, MD⁶, David B. Miklos, MD, PhD⁷, Caron A Jacobson, MD, MMSc⁸, Javier L. Munoz⁹, Patrick B Johnston, MD, PhD^10*, Samantha M. Jaglowski, MD, MPH¹¹, Ian W. Flinn, MD, PhD¹², Tom van Meerten, MD, PhD^13*, Miguel-Angel Perales, MD¹⁴, Peter Vandenberghe, MD, PhD¹⁵, Peter A. Riedell, MD¹⁶, Kathleen Dorritie, MD¹⁷, David Szwajcer, MD^18*, Dimitrios Tzachanis, MD, PhD¹⁹, Saran Vardhanabhuti^20*, Linqiu Du^20*, Simone Filosto^20*, Shilpa A. Shahani, MD^20*, Christina To, MD²¹ and Jason Westin, MD²²

https://ash.confex.com/ash/2023/webprogram/Paper173873.html

 

2051 Extracellular Release of Damaged Mitochondria Induced By Cytotoxic Conditioning Exacerbates Graft-Versus-Host Disease

Vijith Vijayan, PhD¹, Hao Yan, PhD^2*, Juliane Lohmeyer, PhD^3*, Kaylin Prentiss, BS^3*, Rachana Patil, MS^3*, Giulia Barbarito, MS^1*, Ivan Lopez, BS^3*, Aly Elezaby, MD, PhD^3*, Kolten Peterson, BS^4*, Jeanette Baker, PhD^2*, Nicolai Ostberg, MS^3*, Alice Bertaina, MD, PhD⁵, Robert S. Negrin, MD⁶, Daria Mochly-Rosen, PhD^3*, Kenneth I. Weinberg, MD^7* and Bereketeab Haileselassie, MD^1*

https://ash.confex.com/ash/2023/webprogram/Paper179456.html

 

2095 ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Frederick L. Locke, MD¹, Javier L. Munoz², Michael T. Tees, MD³, Lazaros J. Lekakis^4*, Herbert A. Eradat, MD⁵, Sven de Vos, MD, PhD^5*, Rajneesh Nath^6*, Don A. Stevens, MD⁷, Shahbaz A. Malik, MD⁸, Geoffrey P. Shouse, PhD, DO⁹, Mehdi Hamadani, MD¹⁰, Olalekan O. Oluwole, MBBS¹¹, Miguel-Angel Perales, MD¹², David B. Miklos, MD, PhD¹³, Anh Nguyen^14*, Amy Feng^14*, Lynn Navale^14*, Elaine Murray^14*, Greg P. Kaufman^14*, Kazuharu Kai^14*, John B. Le Gall^14* and Sattva S. Neelapu, MD¹⁵

https://ash.confex.com/ash/2023/webprogram/Paper189196.html

 

2119 Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Vishal K Gupta, MD¹, Gregory W Roloff, MD², Lori S. Muffly, MD³, Ibrahim Aldoss⁴, Noam E. Kopmar, MD⁵, Chenyu Lin, MD⁶, Simone E. Dekker, MD, PhD⁷, Nikeshan Jeyakumar, MD^3*, Timothy E O'Connor, MD⁸, Amy Zhang, PhD^9*, Katharine Miller, PhD, MPH^9*, Kaitlyn C Dykes, MD^10*, Mohamed Ahmed¹¹, Danielle Bradshaw, MD^12,13*, Santiago Mercadal, MD^14*, Marc Schwartz, MD^15*, Sean Tracy, MD, PhD¹⁶, Bhagirathbhai Dholaria, MBBS¹⁷, Michal Kubiak, MD¹³, Akash Mukherjee, MD^18*, Navneet Majhail, MD¹⁹, Minoo Battiwalla, MD¹⁹, Luke Mountjoy, DO²⁰, Shabaz Malik, MD^21*, John Mathews, MD^22*, Paul Shaughnessy, MD²³, Aaron C. Logan, MD, PhD²⁴, Abdullah Ladha, MD^25*, George Yaghmour, MD^26,27, Anjali S. Advani, MD²⁸, Maryann Stefan^28*, Caitlin Guzowski, MBA^29*, Rasmus T. Hoeg, MD^30*, Talal Hilal, MD³¹, Jozal Moore, MD³², Kristen M. O'Dwyer, MD³², Stephanie B. Tsai, MD, MS⁸, Joshua Sasine, MD³³, Catherine J. Lee, MD³⁴, Vamsi K. Kota, MD¹³, Divya Koura, MD¹⁰, Muthu Veeraputhiran, MD^18*, Betsy Blunk^35*, Jessica T. Leonard, MD³⁶, Wendy Stock, MD³⁷, Ahmed Galal, MD⁶, Vinod Pullarkat, MD³⁸, Ryan D Cassaday, MD⁵, Bijal D. Shah, MD³⁹, Rawan Faramand, MD⁴⁰ and Caspian H. Oliai, MD⁴¹

https://ash.confex.com/ash/2023/webprogram/Paper182915.html

 

2120 Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, MBBS¹, Patrick M. Reagan, MD², David B. Miklos, MD, PhD³, Frederick L. Locke, MD⁴, Andre Goy, MD⁵, Caron A Jacobson, MD, MMSc⁶, Javier L. Munoz⁷, Edouard Forcade, MD, PhD^8*, Max S. Topp, MD^9*, Dan Zheng, PhD^10*, Ana Nunes, PharmD^10*, Wangshu Zhang, PhD^10*, Rhine R. Shen, PhD^10*, Ioana Kloos, MD^10*, Marie José Kersten, MD, PhD¹¹ and Michael L. Wang, MD¹²

https://ash.confex.com/ash/2023/webprogram/Paper174681.html

 

2121 Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Swetha Kambhampati, MD¹, Hai-Lin Wang, MPH^2*, Jiali Yan, MS^2*, Alex F. Herrera, MD³, Matthew J. Frank, MD, PhD⁴, Leslie L. Popplewell, MD, FACP, MPH¹, Nausheen Ahmed, MD⁵, Yi Lin, MD, PhD⁶, Frederick L. Locke, MD⁷, Paola Ghione, MD, MSEpi⁸, John G. Gribben, MD, DSc⁹, Timothy Best^2*, Christine Fu, PhD^2*, Sara Beygi, MD^2*, Markqayne D Ray, PharmD^10*, John Bian, PhD^2*, Zhen-Huan Hu, MPH^2*, Fang Sun, MD, PhD^2*, Marcelo Pasquini, MD, MS¹¹ and Caron A Jacobson, MD, MMSc¹²

https://ash.confex.com/ash/2023/webprogram/Paper178629.html

 

2122 Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, MBBS^1*, Olga Goloubeva^2*, Philip Margiotta, MD³, Hanan Alharthy, MBBS⁴, Imari Patel^3*, Ali Bukhari, MD, MS², Jennie Law, MD⁵, Seung Tae Lee, MD⁶, Mehmet H. Kocoglu, MD⁷, Jean A. Yared, MD⁸, Nancy M. Hardy, MD⁹, Maggie Nelson, PharmD^10*, Joseph P McGuirk, DO¹⁰, Aaron P. Rapoport, MD², Saurabh Dahiya^11,12* and Forat Lutfi, MD^10*

https://ash.confex.com/ash/2023/webprogram/Paper183002.html

 

3499 Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Shonali Midha, MD, BS^1*, Ashwath Gurumurthi, MBBS^2*, Patrick Costello^3*, Robert A. Redd, MS^4*, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP⁵, Omar Castaneda, MD⁵, Rebecca Gonzalez, PharmD^5*, Filip Ionescu, MD⁶, Mahmoud Gaballa, MD², Nilesh Kalariya, PhD, RN^2*, Jack Khouri, MD⁷, Danai Dima, MD⁸, Mehmet H. Kocoglu, MD⁹, Douglas Sborov, MD, MS¹⁰, Charlotte B Wagner, PharmD^10*, Shebli Atrash, MD^11*, Peter M. Voorhees, MD¹¹, Hamza Hashmi, MD^12*, James A Davis, PharmD^12*, Peter A. Forsberg, MD^13*, Joseph P McGuirk, DO¹⁴, Leyla Shune, MD¹⁵, Megan Herr, PhD¹⁶, Ran Reshef, MD, MSc¹⁷, Yi Lin, MD, PhD¹⁸, Myo Htut, MD¹⁹, Thomas Martin, MD²⁰, Surbhi Sidana, MD²¹, Doris K. Hansen, MD⁵, Omar Nadeem, MD³ and Krina K. Patel, MD, MSc²²

https://ash.confex.com/ash/2023/webprogram/Paper187565.html

 

3501 Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Niels W.C.J. Van De Donk^1*, Surbhi Sidana, MD², Jordan M. Schecter³, Carolyn Chang Jackson³, Nikoletta Lendvai^3*, Kevin C De Braganca³, Ana Slaughter^4*, Carolina Lonardi^5*, Philip Vlummens^6*, Helen Varsos^3*, Christina Corsale^3*, Deepu Madduri^3*, Shirin Jadidi^3*, Junchen Gu^7*, Hao Zhao^7*, Katherine Li^7*, Erin Lee^8*, Loreta Marquez^3*, Man Zhao^9*, Tzu-min Yeh^3*, Diana Chen^10*, Erika Florendo^11*, Nitin Patel^11*, Muhammad Akram^11*, Jaime Gellego Perez-Larraya^12* and Paula Rodriguez Otero, MD, PhD^13*

https://ash.confex.com/ash/2023/webprogram/Paper178743.html

 

3502 Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Chenyu Lin, MD¹, Stephanie B. Tsai, MD, MS², Gregory W Roloff, MD³, Amy Zhang, PhD^4*, Ibrahim Aldoss⁵, Noam E. Kopmar, MD⁶, Simone E. Dekker, MD, PhD⁷, Nikeshan Jeyakumar, MD^4*, Vishal K Gupta, MD⁸, Timothy E O'Connor, MD², Kaitlyn C Dykes, MD^9*, Mohamed Ahmed¹⁰, Bhagirathbhai Dholaria, MBBS¹¹, Hector Zambrano^12*, Danielle Bradshaw, MD^13*, Aaron C. Logan, MD, PhD¹⁴, Sean Tracy, MD, PhD¹⁵, Michal Kubiak, MD¹³, Melhem M. Solh, MD¹⁶, Santiago Mercadal, MD^17*, Marc Schwartz, MD^18*, Akash Mukherjee, MD^19*, Minoo Battiwalla, MD¹², Paul Shaughnessy, MD^20*, Navneet Majhail, MD²¹, Luke Mountjoy, DO^22*, Shahbaz A. Malik, MD²³, John Mathews, MD^24*, Abdullah Ladha, MD^25*, Anjali S. Advani, MD²⁶, Maryann Stefan^26*, Caitlin Guzowski, MBA^16*, Rasmus T. Hoeg, MD^27*, Talal Hilal, MD²⁸, Jozal Moore, MD²⁹, Kristen M. O'Dwyer, MD²⁹, Joshua Sasine, MD¹⁰, Catherine J. Lee, MD¹⁷, Vamsi K. Kota, MD¹³, Divya Koura, MD⁹, Muthu Veeraputhiran, MD^19*, Betsy Blunk^12*, Jessica T. Leonard, MD⁷, Caspian H. Oliai, MD⁸, Veronika Bachanova, MD, PhD¹⁵, Wendy Stock, MD³, Vinod Pullarkat, MD⁵, Ryan D Cassaday, MD⁶, Katharine Miller, PhD, MPH^4*, Lori S. Muffly, MD⁴, Ahmed Galal, MD¹, Bijal D. Shah, MD³⁰ and Rawan Faramand, MD³⁰

https://ash.confex.com/ash/2023/webprogram/Paper182380.html

 

3560 Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Alejandro Villar-Prados, MD, PhD1, Everett H. Meyer, MD, PhD2, Katherine Sutherland, PA-C3*, Robert S. Negrin, MD4, Sally Arai, MD5, Matthew J. Frank, MD, PhD6, Laura Johnston7, Robert Lowsky, MD8*, David B. Miklos, MD, PhD6, Lori S. Muffly, MD9, Saurabh Dahiya6*, Andrew R. Rezvani, MD, BA10*, Surbhi Sidana, MD7, Parveen Shiraz, MD7*, Judith Shizuru, MD, PhD11*, Wen-Kai Weng, MD, PhD6, Melody Smith, MD, MS12, Sushma Bharadwaj, MD, MS6, John Tamaresis, PhD13*, Anna Pavlova, MD/PhD14* and Scott McClellan14*

https://ash.confex.com/ash/2023/webprogram/Paper188162.html

 

3777 Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Andrew J. Cowan, MD¹, Krish Patel, MD², Jakub Svoboda, MD³, Bijal D. Shah, MD⁴, Bruce D. Cheson⁵, Georges Azzi, MD^6*, Viral Rabara, MD^7*, Lori S. Muffly, MD⁸, Heidi Simmons, PhD⁹, Stephen Thuillier, PharmD¹⁰ and Jessica T. Leonard, MD¹¹

https://ash.confex.com/ash/2023/webprogram/Paper187586.html

 

4784 The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Eli Muchtar, MD¹, Vaishali Sanchorawala, MD², Hamza Hassan, MD^3*, Ute Hegenbart^4*, Stefan Schonland^5*, Hans C. Lee, MD⁶, Muzaffar H. Qazilbash, MD⁷, Andrew Kin, MD⁸, Christiane A. Houde, BS^9*, Francis Buadi, MD¹⁰, Angela Dispenzieri, MD¹¹, Eapen K. Jacob, MD¹², Sally Arai, MD¹³, Michelle Chin MD^14,15*, Rajshekhar Chakraborty, MD¹⁶, Suzanne Lentzsch, MD, PhD¹⁷, Hila Magen, MD^18*, Eden Shkury^19*, Caitlin Sarubbi, MD^20*, Heather Landau, MD²¹ and Morie A Gertz, MD^11*

https://ash.confex.com/ash/2023/webprogram/Paper188115.html

 

4862 Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, M.D.¹, Jacques Azzi², Brenda W Cooper, MD³, Abhinav Deol, MD^4*, John DiPersio⁵, Divya Koura, MD⁶, Brian McClune, DO⁷, Lori S. Muffly, MD⁸, Muhammad Umair Mushtaq, MD⁹, Rupa Narayan, MD¹⁰, Hyung Chan Suh, MD, PhD¹¹, Gregory Yanik, MD^12*, Sritama Nath, PhD^13*, Jennifer Whangbo, MD, PhD¹³ and Guenther Koehne, MD, PhD¹⁴

https://ash.confex.com/ash/2023/webprogram/Paper180990.html

 

4864 Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, MD¹, Caron A Jacobson, MD, MMSc², Armin Ghobadi, MD³, David B. Miklos, MD, PhD⁴, Lazaros J. Lekakis^5*, Clare Spooner, BSc, MBBS^6*, Jenny J. Kim, MD, MS⁷, Harry Miao, MD, PhD⁶, Allen Xiaodong Xue, PhD^6*, Yan Zheng, MD, PhD, MS^6* and Frederick L. Locke, MD⁸

https://ash.confex.com/ash/2023/webprogram/Paper174288.html

 

4880 Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Charlotte B Wagner, PharmD^1*, Karen Sweiss, PharmD², Eric Anto, M.S.^1*, Rebecca Gonzalez, PharmD^3*, Omar Alexis Castaneda Puglianini, MD⁴, Ciara L. Freeman, PhD, MSc, FRCPC, MRCP⁵, Filip Ionescu, MD⁶, Krina K. Patel, MD, MSc⁷, Christopher Ferreri, MD^8*, Mahmoud Gaballa, MD⁹, Leyla Shune, MD¹⁰, Joseph P McGuirk, DO¹¹, Surbhi Sidana, MD¹², Vanna Hovanky, MS^12*, Jack Khouri, MD¹³, Danai Dima, MD¹⁴, Hamza Hashmi, MD^15*, James A Davis, PharmD^16*, Aimaz Afrough, MD¹⁷, Gurbakhash Kaur, MD, MA¹⁸, Larry D. Anderson Jr., MD, PhD¹⁹, Peter A. Forsberg, MD^20*, Megan Herr, PhD²¹, Doris K. Hansen, MD²², Douglas Sborov, MD, MS¹ and Mehmet H. Kocoglu, MD²³

https://ash.confex.com/ash/2023/webprogram/Paper187440.html

 

5000 One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

David C Shyr, MD¹, Robert Lowsky, MD^2*, Weston Miller, MD^3*, Mark A. Schroeder, MD⁴, Tonia Buchholz, PhD^5*, Kirstin Dougall, MBA^6*, Allison Intondi^5*, Alexandra Charles^7*, Josh Lehrer, MD, MPhil^5*, Ali Bouge^7*, Stacey Wolf^7*, Blair MacDonald^7*, Hena Din^7*, Alana Lerner, PhD^5*, Manal Amoury^3*, Sebastien Treusch, PhD^3*, Glen Chew^8*, Brian Silva^8*, Haider Mashhedi^3*, Vincent Siu^3*, Ian Perrone^3*, Twaritha Vijay^3*, Aayami Jain^3*, Kristina Krassovsky^8*, William Matern^8*, Premanjali Lahiri^3*, Ryan Rodriguez, PhD^3*, Jason Skowronski^3,9*, Arpit Batish^7*, Dana Margittai^7*, Prachi Wani^7*, Timothy Van Horn^7*, Claudia Flautero^7*, Rosalva Flores^3*, Jade Lee^3*, Keri Tate^10*, Maria-Grazia Roncarolo, MD¹¹, Steven Feldman, PhD^12*, John DiPersio¹³ and Matthew Porteus, MD, PhD¹⁴

https://ash.confex.com/ash/2023/webprogram/Paper188963.html

 

ASH SCIENTIFIC WORKSHOP

CRTI

ASH-a-Palooza
Program: Trainee Activities and Services
Session: Blood Drop: CRTI

Friday, December 8, 2023, 4:35 PM-4:45 PM

Friday, December 8, 2023, 4:50 PM-5:00 PM

Surbhi Sidana, MD

https://ash.confex.com/ash/2023/webprogram/Paper191571.html

Keynote Address MRI Luncheon

Program: Scientific Symposia

Saturday, December 9, 2023

11:15 a.m. – 1:00 p.m.

Marriott Marquis San Diego Marina

Marina Ballroom F and G

333 W Harbor Drive, San Diego, CA 92101

Melody Smith, MD, MS

 

The Impact of the Microbiota on Immunotherapy of Hematological Malignancies

Program: Scientific Symposia

Microbiota and the Development of Hematological Malignancies

Sunday, December 10, 2023: 9:30 AM-10:45 AM

Room 25 (San Diego Convention Center)

Melody Smith, MD, MS

https://ash.confex.com/ash/2023/webprogram/Session24834.html

 

Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma

Program: Education Program
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies

Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Adverse Events

Monday, December 11, 2023, 10:30 AM-11:45 AM

Surbhi Sidana, MD

https://ash.confex.com/ash/2023/webprogram/Paper172223.html